The 340B PATIENTS Act of 2024 The 340B Pharmaceutical Access To Invest in Essential, Needed Treatments & Support Act of 2024
One of the critical impacts of HB 7635 is the clarification it provides regarding the obligations of drug manufacturers towards covered entities under the 340B program. The bill prohibits manufacturers from placing conditions that hinder these entities from purchasing discounted drugs. With this bill, covered entities are empowered to contract pharmacies to dispense drugs purchased under the 340B pricing agreements. This aims to bolster community healthcare services by ensuring that these entities can navigate the regulatory environment more effectively and utilize the savings from drug purchases.
House Bill 7635, designated as the 340B PATIENTS Act of 2024, seeks to amend title III of the Social Security Act to enhance the accessibility of drugs provided through the 340B drug discount program. The bill emphasizes the need for drug manufacturers to sell covered drugs to covered entities at mandated discount rates, making it clear that these discounts must apply regardless of the manner in which the drugs are dispensed. This legislative initiative aims to secure funding for healthcare facilities such as hospitals and clinics, enabling them to stretch their limited resources while serving more patients efficiently.
Notable contention surrounding HB 7635 includes concerns raised by some stakeholders regarding the imposition of civil monetary penalties on manufacturers who violate the bill's provisions. Critics express apprehension that such penalties may lead to higher drug prices or restricted access if manufacturers decide to minimize the risks associated with compliance. Advocates for the bill argue that these enforcement measures are vital to uphold the intentions of the 340B program, foster competitive pricing, and ensure the ongoing funding of essential community healthcare services.